Literature DB >> 33419814

Combination of p53 and Ki67 as a Promising Predictor of Postoperative Recurrence of Meningioma.

Atsufumi Nagahama1, Masakazu Yashiro2,3, Toshiyuki Kawashima1, Kosuke Nakajo1, Hiroki Morisako1, Takehiro Uda1, Kentaro Naito1, Tsutomu Ichinose1, Kenji Ohata1, Takeo Goto1.   

Abstract

BACKGROUND: Meningioma is a common intracranial tumor originating from arachnoid cap cells. Meningiomas are generally benign tumors curable by one-time resection. However, some meningiomas regrow and invade into the dura mater, and thus frequently require additional treatment. A useful marker to predict the regrowth of meningioma is desired. This study aimed to clarify the significance of p53 and Ki67 for postoperative recurrence of meningioma.
MATERIALS AND METHODS: The expression of p53 and Ki67 in 215 intracranial or intraspinal meningiomas was investigated by immunohistochemistry.
RESULTS: Of the 215 meningiomas, 35 cases (16.3%) were p53-positive and 49 cases (22.8%) were Ki67-positive. Multivariate analysis revealed Ki67 and p53 status as being significantly correlated with recurrence. Positivity for either Ki67- or p53 was significantly associated with poor recurrence-free survival.
CONCLUSION: Combined p53 and Ki67 status might represent a useful independent predictive marker for recurrence of meningioma. Copyright
© 2021, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Ki67; Meningioma; immunostaining; p53; recurrence

Year:  2021        PMID: 33419814     DOI: 10.21873/anticanres.14766

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  1 in total

1.  P53 Suppressor Gene Tissue Microarray-based Protein Expression Analysis in Meningiomas.

Authors:  Dimitrios Roukas; Anastasios Kouzoupis; Despoina Spyropoulou; George Papanastasiou; Evangelos Tsiambas; George Tsouvelas; Evangelos Falidas; Vasileios Ragos; Dimitrios Peschos; Loukas Manaios; Spyros Katsinis; Arezina Manoli; Sotirios Papouliakos; Andreas C Lazaris; Nikolaos Kavantzas
Journal:  In Vivo       Date:  2022 Sep-Oct       Impact factor: 2.406

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.